多组织生物标志物独立且叠加预测前列腺癌病理结局
本研究在381例和260例低危前列腺癌患者中,评估血浆TGFβ1、IL6-SR及组织GEMCaP、CCP评分对前列腺切除术后不良病理的预测价值。结果显示CCP和GEMCaP评分独立且叠加预测升级/升期,而血浆标志物无显著关联。
要点
- CCP和GEMCaP评分独立预测低危前列腺癌术后病理升级/升期。
- 血浆TGFβ1和IL6-SR与不良病理无显著关联。
- 两组织评分相关性弱,提示信息互补。
核心结论
- 基于DNA和RNA的组织生物标志物评分可独立且叠加预测低危前列腺癌患者前列腺切除术后的不良病理。
研究设计与样本
- 病例对照研究,纳入活检GG1、PSA≤10 ng/mL、临床分期≤T2且接受即刻前列腺切除术的低危前列腺癌患者,来自加州大学旧金山分校381例和华盛顿大学260例。
主要发现
- 357例无升级/升期,236例轻微事件,67例主要事件。
- TGFβ1和IL6-SR与任何升级/升期均无统计学显著关联。
- Gleason pattern 3组织的CCP和GEMCaP评分在单变量分析中与轻微和主要升级/升期直接相关。
- 多变量分析中,CCP评分预测轻微升级/升期OR 1.62(95%CI 1.05-2.49),主要升级/升期OR 2.26(95%CI 1.05-4.90),p=0.04。
- GEMCaP评分预测轻微升级/升期OR 1.05(95%CI 1.03-1.08),主要升级/升期OR 1.07(95%CI 1.04-1.11),p<0.01。
关键数值与推荐
- CCP和GEMCaP评分取自Gleason pattern 3组织,多变量模型控制PSA、阳性活检核心百分比、年龄和临床中心。
- 在升级肿瘤中,GEMCaP和CCP评分在高分级肿瘤中倾向于更高。
临床怎么用
- 对于临床低危前列腺癌患者,基于组织DNA和RNA的生物标志物评分可提供独立于临床参数的术后病理风险信息。
局限性
- 主要局限性是使用前列腺切除组织的虚拟活检作为前列腺活检的替代。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Distinguishing indolent from aggressive prostate cancer remains a key challenge for decision making regarding prostate cancer management. A growing number of biomarkers are now available to help address this need, but these have rarely been examined together in the same patients to determine their potentially additive value. OBJECTIVE: To determine whether two previously validated plasma markers (transforming growth factor β1 [TGFβ1] and interleukin-6 soluble receptor [IL6-SR]) and two validated tissue scores (the Genomic Evaluators of Metastatic Prostate Cancer [GEMCaP] and cell cycle progression [CCP] scores) can improve on clinical parameters in predicting adverse pathology after prostatectomy, and how much they vary within tumors with heterogeneous Gleason grade. DESIGN, SETTING, AND PARTICIPANTS: A case-control study was conducted among men with low-risk cancers defined by biopsy grade group (GG) 1, prostate-specific antigen (PSA) ≤10 ng/mL, and clinical stage ≤ T2 who underwent immediate prostatectomy. We collected paraffin-fixed prostatectomy tissue and presurgical plasma samples from 381 cases from the University of California, San Francisco, and 260 cases from the University of Washington. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Pathologic outcomes were minor upgrading/upstaging (GG 2 or pT3a) or major upgrading/upstaging (GG ≥ 3 or ≥ pT3b), and multinomial regression was performed to determine putative markers' ability to predict these outcomes, controlling for PSA, percent of positive biopsy cores, age, and clinical site. For upgraded tumors, a secondary analysis of the GEMCaP and CCP scores from the higher-grade tumor was also performed to evaluate for heterogeneity. RESULTS AND LIMITATIONS: Overall, 357 men had no upgrading/upstaging event at prostatectomy, 236 had a minor event, and 67 had a major event. Neither TGFβ1 nor IL6-SR was statistically significantly associated with any upgrading/upstaging. On the contrary, both the CCP and the GEMCaP score obtained from Gleason pattern 3 tissue were directly associated with minor and major upgrading/upstaging on univariate analysis. The two scores correlated with each other, but weakly. On multinomial analysis including both scores in the model, the CCP score predicted minor upgrading/upstaging (odds ratio [OR] 1.62, 95% confidence interval [CI] 1.05-2.49) and major upgrading/upstaging (OR 2.26, 95% CI 1.05-4.90), p = 0.04), and the GEMCaP score also predicted minor upgrading/upstaging (OR 1.05, 95% CI 1.03-1.08) and major upgrading/upstaging (OR 1.07, 95% CI 1.04-1.11), p < 0.01). The other clinical parameters were not significant in this model. Among upgraded tumors including both Gleason patterns 3 and 4, both the GEMCaP and the CCP score tended to be higher from the higher-grade tumor. The main limitation was the use of virtual biopsies from prostatectomy tissue as surrogates for prostate biopsies. CONCLUSIONS: Biomarker signatures based on analyses of both DNA and RNA significantly and independently predict adverse pathology among men with clinically low-risk prostate cancer undergoing prostatectomy. PATIENT SUMMARY: Validated biomarker scores derived from both prostate cancer DNA and prostate cancer RNA can add independent information to help predict outcomes after prostatectomy.
引用
- Cooperberg MR, Cowan JE, Lindquist KJ, et al. Multiple Tissue Biomarkers Independently and Additively Predict Prostate Cancer Pathology Outcomes. Eur Urol. 2020. PMID: 33148472. doi:10.1016/j.eururo.2020.09.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。